Clinical outcomes in high‐hypoglycaemia‐risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first‐generation basal insulin analogue in the United States : Results from the DELIVER High Risk real‐world study
Endocrinology Diabetes & Metabolism2021Vol. 5(1), pp. e00306–e00306
Citations Over Time
Sean D. Sullivan, Nick Freemantle, Rishab Gupta, Jasmanda Wu, Charlie Nicholls, Jukka Westerbacka, Timothy S. Bailey
Abstract
In patients with T2D at high risk of hypoglycaemia, switching to Gla-300 or Gla-100/IDet achieved similar HbA1c reductions and glycaemic goal attainment, but Gla-300 switchers had a significantly lower risk of hypoglycaemia associated with an inpatient/ED contact during 12 months after switching.
Related Papers
- → Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir(2006)82 cited
- → PDB56 THE IMPACT OF STARTING INSULIN GLARGINE VERSUS INSULIN DETEMIR ON QUALITY OF LIFE (QOL) AND TREATMENT SATISFACTION (TS) IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON ORAL GLUCOSE-LOWERING DRUGS (OGLDS)(2009)
- → Real-world clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen vs insulin detemir disposable pen in a US managed care setting(2011)
- Экономический прогноз применения нового аналога инсулина гларгин при сахарном диабете 2 типа(2016)